Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Expenses: 2024-2025

Historic Accumulated Expenses for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $14.6 million.

  • Kura Oncology's Accumulated Expenses rose 16.93% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 16.93%. This contributed to the annual value of $17.5 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Accumulated Expenses amounted to $14.6 million in Q3 2025, which was up 45.53% from $10.0 million recorded in Q2 2025.
  • Kura Oncology's 5-year Accumulated Expenses high stood at $17.5 million for Q4 2024, and its period low was $6.1 million during Q1 2024.